ClinicalTrials.gg
CompletedNCT01846234SALTUpdated Oct 22, 2013

Sodium Intake in Multiple Sclerosis

An observational study in Multiple Sclerosis, sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia. Completed at 1 site in Argentina. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2013-10-22.

Sponsored by Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
132
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Multiple Sclerosis with a site in Argentina — 4 open to participants now, 13 under way, 10 of them phase 3. Multiple Sclerosis · Argentina.

Enrollment
16th of 18
132 · median 453
Started
2010
with 2 others
Observational
18 of 53
1 open now
Registered
27th of 53
by date

Among the 53 studies in Multiple Sclerosis with a site in Argentina, this one is the 16th largest by enrollment of the 18 observational ones that give a count, is one of 3 that started in 2010, is one of 18 observational ones, and was the 27th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 53 studies in Multiple Sclerosis with a site in Argentina are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Multiple Sclerosis with a site in Argentina, or all of them as a file.
02

Study summary

Recently, it has been shown that salt (ClNa, sodium chloride) can modulate the differentiation of human and mouse TH17 cells. Indeed, mice feed with high sodium diet were described to develop more aggressive course of EAE (Experimental Autoimmune Encephalitis).

However, the role of sodium intake in MS has not been investigated. In this study we investigate the effect of sodium intake in Multiple Sclerosis (MS) clinical and radiological activity.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis
  • Salt
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of 70 patients with relapsing-remitting MS according to McDonald criteria1 were recruited from the MS clinic at FLENI by attending neurologists. A second group of 52 relapsing-remitting MS patients was recluted later.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is between 18 and 50 years old
  • Subject has diagnosis of relapsing-remitting MS according to McDonald criteria (2010)

Exclusion criteria

Exclusion Criteria:

  • Patient who had hyponatremia in the last 90 days
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
132 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • MS patients

    MS patients

06

What researchers measure

Primary outcomes

  1. Exacerbation rate

    Number of disease relapses during follow up time according to salt consumption

    Time frame: 2 years

Secondary outcomes

  1. Radiological activity

    Number of new lesions in MRI

    Time frame: One year

07

Study locations

1 site
  • FLENI
    Buenos Aires, 1428, Argentina
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2013
First posted
May 3, 2013
Start
Nov 2010
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Last update
Oct 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01846234
Lead sponsor
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
Responsible party
Mauricio F. Farez (Research Associate, Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia) — Principal investigator
First posted
May 3, 2013
Start date
Nov 2010
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Oct 22, 2013

Study contacts

Mauricio F Farez, MD MPH
principal investigator · Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion